Literature DB >> 22379426

Commentary: should cost and comparative value of treatments be considered in clinical practice guidelines?

Ethan Basch, Mark R Somerfield, Ann Partridge, Lowell Schnipper, Gary H Lyman.   

Abstract

Year:  2011        PMID： 22379426      PMCID： PMC3219470          DOI： 10.1200/JOP.2011.000414

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  8 in total

1.  How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement.

Authors:  Steven D Pearson; Peter B Bach
Journal:  Health Aff (Millwood)       Date:  2010-10       Impact factor: 6.301

Review 2.  Systematic review: reliability of compendia methods for off-label oncology indications.

Authors:  Amy P Abernethy; Gowri Raman; Ethan M Balk; Julia M Hammond; Lori A Orlando; Jane L Wheeler; Joseph Lau; Douglas C McCrory
Journal:  Ann Intern Med       Date:  2009-02-16       Impact factor: 25.391

3.  Comparative effectiveness research in oncology: the need for clarity, transparency and vision.

Authors:  Gary H Lyman
Journal:  Cancer Invest       Date:  2009-07       Impact factor: 2.176

Review 4.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

5.  Bending the cost curve in cancer care.

Authors:  Thomas J Smith; Bruce E Hillner
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

6.  Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients.

Authors:  Elenir B C Avritscher; Ya-Chen T Shih; Charlotte C Sun; Richard J Gralla; Steven M Grunberg; Ying Xu; Linda S Elting
Journal:  J Support Oncol       Date:  2010 Nov-Dec

7.  Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.

Authors: 
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

8.  Economic Evaluation of a New Antiemetic Drug - Palonosetron versus Ondansetron : Assessment of the Drug Price Ratio in Five European Countries.

Authors:  Rosanna Tarricone; Federica Girolami
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 3.580
  8 in total
  3 in total

1.  Preparing for success with comparative effectiveness research.

Authors:  Thomas G Roberts
Journal:  Oncologist       Date:  2013-06

Review 2.  Cost, coverage, and comparative effectiveness research: the critical issues for oncology.

Authors:  Steven D Pearson
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

3.  Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.

Authors:  Luigi Celio; Francesca Ricchini; Filippo De Braud
Journal:  Patient Prefer Adherence       Date:  2013-05-07       Impact factor: 2.711
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.